Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
interleukin-2
Biotech
Nektar claims ph. 2 alopecia success after excluding 4 patients
Rezpeg significantly reduced scalp hair loss severity in an analysis that excluded four patients who ‘should never have been enrolled’ in the trial.
Darren Incorvaia
Dec 16, 2025 5:05pm
Synthekine hopes new IL-2 will be the high-alpha in a beta class
Apr 10, 2024 9:50am
Gilead pays $43.5M for Xilio's early-phase IL-12 prospect
Mar 28, 2024 8:08am
Mural wants to paint new picture in IL-2 after Alkermes spinout
Nov 15, 2023 8:56am
Coya deems dementia drug R&D plan 'premature,' switches focus
Jun 12, 2023 9:00am
Neoleukin lays off 70% of staff, hunts for strategic alternative
Mar 9, 2023 5:45am
